{"id":"NCT00380068","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension","officialTitle":"ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-07","completion":"2009-05","firstPosted":"2006-09-25","resultsPosted":"2010-11-19","lastUpdate":"2012-04-05"},"enrollment":224,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"Ambrisentan","otherNames":["Letairis","Volibris"]}],"arms":[{"label":"Ambrisentan","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertension (PAH), long-term treatment success, and survival.","primaryOutcome":{"measure":"Change From Baseline to Week 24 in 6 Minute Walk Distance (6MWD)","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Ambrisentan","deltaMin":20.5,"sd":65.64}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":39,"countries":["United States","Australia","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.gilead.com"]},"adverseEventsSummary":{"seriousAny":{"events":97,"n":224},"commonTop":["oedema peripheral","headache","upper respiratory tract infection","dyspnoea","nasal congestion"]}}